BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-fda-oncology-animal-testing-guidance-comment-july2026@catalyst-calendar.local
DTSTAMP:20260720T200641Z
DTSTART:20260731T035900Z
DTEND:20260731T035900Z
SUMMARY:FDA肿瘤药非临床安全研究动物试验精简指南意见截止窗口
DESCRIPTION:FDA发布肿瘤药物非临床安全研究精简草案指南，建议在部分生物制品和偶联药物中减少不必要动物试验，并使用New Approach Methodologies。意见建议在2026年7月30日前提交。该政策影响肿瘤ADC、双抗、生物制品和早期临床开发成本/周期预期。\\nImpact score: 56\\nExpected: 意见截止后，市场关注FDA最终指南是否降低早期肿瘤生物制品、ADC和偶联产品的非临床包袱，或改变IND准备节奏。\\nAffected: XBI(etf\, mixed\, score 55)\; IBB(etf\, mixed\, score 50)\; 688506.SH(theme\, mixed\, score 52)\; 09926.HK(theme\, mixed\, score 50)\; BNTX(theme\, mixed\, score 48)\\nSources: FDA animal testing oncology guidance press release: https://www.fda.gov/news-events/press-announcements/fda-issues-draft-guidance-cut-unnecessary-animal-testing-cancer-drugs\\nFDA actions to modernize clinical development: https://www.fda.gov/industry/fda-actions-accelerate-and-modernize-early-and-late-stage-clinical-development\\nFDA recently issued guidance documents: https://www.fda.gov/vaccines-blood-biologics/biologics-guidances/recently-issued-guidance-documents\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-fda-oncology-animal-testing-guidance-comment-july2026
CATEGORIES:policy\,MACRO\,FDA\,guidance\,oncology\,nonclinical safety\,animal testing\,NAMs
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: FDA肿瘤药非临床安全研究动物试验精简指南意见截止窗口
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: FDA肿瘤药非临床安全研究动物试验精简指南意见截止窗口
END:VALARM
END:VEVENT
END:VCALENDAR